bstructive sleep apnea (OSA) secondary to periodic collapse of the upper airway during sleep is a strong and independent risk factor for hypertension and cardiovascular diseases. [1] [2] [3] [4] [5] The prevalence of OSA is reported as 23% to 35% in unse lected hypertensive populations 6-9 and 65% to 85% among patients with resistant hypertension. [10] [11] [12] Cross-sectional studies reported that the severity of OSA is related to BP and that hypertension in subjects with OSA is more likely to be severe and resistant to treatment. 2, 5, 13 Observational studies and clinical trials performed in general and hypertensive populations have related high salt intake to high BP and cardiovascular morbidity and mortality. [14] [15] [16] [17] Dietary salt reduction by 3 g/d has been projected to reduce the annual number of new cases of coronary heart disease in the United States by 60,000 to 120,000, stroke by 32,000 to 66,000, and myocardial infarction by 54,000 to 99,000 and to reduce the annual number of deaths from any cause by 44,000 to 92,000. 18 Furthermore, excessive dietary sodium ingestion contributes importantly to the development of resistant hypertension. We have previously reported that in patients with resistant hypertension, low compared with high dietary intake of salt decreased offi ce systolic and diastolic BP by 22.7 and 9.1 mm Hg, respectively. 19 High salt intake is required for the expression of the deleterious effects of aldosterone excess. Experimental and human studies have shown that targetorgan damage related to aldosterone occurs only in 
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OSA Evaluation
All participants underwent overnight attended polysomnography. Polysomnographic evaluation included airfl ow monitoring with thermocouple, nasal pressure, or both; respiratory effort with piezo belts at the chest and abdominal positions; oxygen saturation as measured by pulse oximetry; heart rate with a single-lead ECG; EEG (C4-A1, C3-A2, O2-A1, O1-A2); submental and tibial electromyograms; and bilateral electrooculograms. Apnea was defi ned as a cessation in airfl ow for Ն 10 s. Hypopnea was defi ned as a reduction in the amplitude of airfl ow of at least 30% for Ն 10 s followed by either a decrease in oxygen saturation of 4% or signs of physiologic arousal (at least 3 s of a activity). Apnea-hypopnea index (AHI) was calculated as the total number of apneas plus hypopneas divided by the hours of sleep. Sleep stage was scored according to Rechtschaffen and Kales criteria. 26 Sleep stage and nocturnal events were continuously supervised by a registered polysomnographic technologist. Scoring of all studies was confi rmed by an American Board of Sleep Medicine diplomat. OSA, which is characterized by preserved and increased respiratory effort despite partial or complete occlusion of the upper airway, was defi ned as an AHI Ն 5. 26 Mild, moderate, and severe OSA were defi ned as an AHI of 5 to 14, 15 to 29, and Ն 30, respectively.
Laboratory Assessment
Biochemical evaluation was carried out in all participants on an outpatient basis. An early morning plasma aldosterone concentration to plasma renin activity (PRA) ratio and serum potassium and creatinine levels were determined in ambulatory patients after sitting for 5 min. A 24-h urinary collection for creatinine, aldosterone (Ualdo), and sodium (UNa) was obtained while the patient maintained his or her routine diet and was performed within 2 weeks before the overnight sleep study. Creatinine clearance (CrCl) was calculated from the serum creatinine level and the 24-h urinary excretion of creatinine and was not corrected for body surface area. Urine collection was considered appropriate if the urinary creatinine level was in the range of 14 to 26 mg/kg/d for men and 11 to 20 mg/kg/d for women. UNa was measured by commercial laboratory tests using standard techniques. PRA and Ualdo levels were measured by radioimmunoassay (Mayo Medical Laboratories).
Statistical Analysis
Values are expressed as mean Ϯ SD unless stated otherwise. Hyperaldosteronism was defi ned as PRA , 1 ng/mL/h and Ualdo Ն 12 m g/24 h according current guidelines. 27 Continuous variables were compared by two-sample t test or Wilcoxon rank sum test, where appropriate. Pearson correlation coeffi cient was used to assess the relationship between AHI and clinical and biochemical parameters. Because of evidence suggesting that salt and aldosterone have combined effects, [20] [21] [22] [23] predictors of severity of OSA were assessed by multiple regression analysis for all patients and for patients with and without hyperaldosteronism separately. Multiple linear regression analysis was used to test the associations between AHI and the covariates, which were age, race, sex, neck circumference, BMI, Ualdo, and UNa. P , .05 was considered signifi cant.
Results
In total, 97 patients with resistant hypertension were evaluated. Overall, 47.4% were men, 48.5% were black, the mean age was 55.2 Ϯ 9.0 years, and the mean offi ce BP was 156.3 Ϯ 22.4/88.9 Ϯ 13.3 mm Hg ( Table 1 ) . the presence of high dietary sodium intake. [20] [21] [22] [23] Because patients with resistant hypertension are characterized by a relative excess of aldosterone, a high degree of salt sensitivity, and a high prevalence of OSA, we hypothesized that effects of excess dietary salt and aldosterone combine to increase the severity of OSA.
Materials and Methods
Patients
Consecutive patients with resistant hypertension referred to The University of Alabama at Birmingham Hypertension Clinic were evaluated prospectively. The protocol was approved by the university's Institutional Review Board for Human Use (IRB number F080821013), and all patients provided written informed consent before study participation.
Resistant hypertension was defi ned as uncontrolled hypertension ( . 140/90 mm Hg) determined at two or more clinic visits despite the use of three or more antihypertensive medications at pharmacologically effective doses. 24 Patients whose offi ce BP was controlled ( Յ 140/90 mm Hg) on four or more antihypertensive medications were also considered to have resistant hypertension. Twenty-four-hour ambulatory BP monitoring was not used to rule out the white-coat effect. All patients were on a stable antihypertensive regimen for at least 4 weeks before biochemical evaluation. No medications were discontinued. All patients on a diuretic were taking hydrochlorothiazide 25 mg daily, and no patients were taking spironolactone, triamterene, or amiloride.
After having the patient sit for at least 5 min, offi ce BP was measured with a mercury sphygmomanometer according to American Heart Association guidelines. 25 Secondary causes of hypertension other than hyperaldosteronism, such as renovascular hypertension, pheochromocytoma, or Cushing syndrome, were excluded by laboratory analysis and radiologic imaging as clinically indicated. Patients with a history of atherosclerotic disease (myocardial infarction or stroke , 6 months), congestive heart failure, current smoking, or diabetes treated with insulin were excluded from study participation. Twenty-eight patients (28.9%) had hyperaldosteronism. Age, sex, BMI, neck circumference, UNa level, and systolic and diastolic BP were similar between patients with and patients without hyperaldosteronism ( Table 2 ) . CrCl was signifi cantly higher among patients with hyperaldosteronism compared with patients with normal aldosterone levels.
Multiple regression analysis showed no significant relationship between AHI and any of the covariates among the entire population ( Table 3 ) . After model selection on the basis of stepwise criteria, only neck circumference correlated signifi cantly with AHI ( P , .0001). Sex, neck circumference, and UNa level were signifi cantly positively related to AHI in patients with hyperaldosteronism ( Table 4 ). The relationship between UNa level and AHI was linear, and there was no threshold. None of the variables were related to AHI in patients without hyperaldosteronism ( Table 5 ) . Notably, BMI showed no correlation among patients with or without hyperaldosteronism.
Discussion
To our knowledge, this study is the fi rst to demonstrate in a hypertensive cohort that dietary salt and aldosterone are associated with severity of OSA. UNa, which could be used for the estimation of dietary salt intake, was positively correlated with AHI in patients with resistant hypertension and hyperaldosteronism. The study also confi rms that OSA is highly prevalent among patients with resistant hypertension. In a recent prospective analysis of 125 patients with resistant hypertension, OSA (defi ned as AHI . 15) was diagnosed in 64% of subjects. 10 In a separate study, OSA (defi ned as AHI Ն 10) was diagnosed in 83% of 41 patients with resistant hypertension seen in a hypertension specialty clinic. 11 Patients took an average of 4.3 Ϯ 1.1 antihypertensive medications, which included angiotensin-converting enzyme inhibitors (61.2%), angiotensin receptor blockers (57.3%), calcium channel blockers (76.7%), b -blockers (77.7%), and diuretics (91.3%). None of the patients were taking mineralocorticoid receptor blockers. Patients were characterized by a long duration of hypertension, normal renal function, high normal Ualdo levels, low PRA levels, and high dietary salt intake ( Table 1 ) .
Overall, the prevalence of OSA was 77.3%. Prevalence of mild, moderate, and severe OSA was 37.1%, 24.7%, and 15.5%, respectively. The mean AHI was signifi cantly greater in men than in women (23.0 Ϯ 19.5 vs 11.2 Ϯ 12.7, P 5 .0001). AHI was similar in blacks and whites. Patients with moderate to severe OSA were more likely to be men (66.7% vs 34.5%, P 5 .0357), had a signifi cantly larger neck circum- of OSA, suggesting that OSA is associated with fl uid retention secondary to the combined effects of high sodium intake, impaired renal function, and overnight rostral fl uid shift from the legs. 34 The present study extends the combined effects of aldosterone and salt to OSA, which is independently associated not only with risk and severity of hypertension but also with cardiovascular morbidity and mortality. Similarly to studies in animals, studies in humans have shown that salt is required for aldosteroneinduced target-organ deterioration. 21 We have demonstrated that similarly to AHI in the current study, urinary protein excretion increased progressively across tertiles of UNa in patients with hyperaldosteronism but not in patients with normal aldosterone levels. 22 In a separate study, we demonstrated the combined effects of aldosterone and salt in promoting dilatation and hypertrophy of the heart. 23 Preliminary evidence from our center indicates that medical treatment with mineralocorticoid receptor blockade can improve OSA, supporting the role of aldosterone and fl uid retention in the pathogenesis of OSA. 35 In a prospective, open-label study, 12 patients with resistant hypertension and moderate to severe OSA (AHI Ն 15) had spironolactone added to their existing antihypertensive regimen for 8 weeks, after which overnight polysomnography was repeated. In all patients, the AHI was reduced by a mean of about 50%. These results support the concept that aldosteroneand sodium-mediated chronic fl uid retention is an important mediator of OSA severity.
The present study is strengthened by its prospective design, sodium excretion measured by 24-h urine collection, and diagnosis of OSA through full-night attended polysomnography. Study limitations include a cross-sectional design and having evaluated patients during ongoing antihypertensive treatment. Although biochemical evaluation of hyperaldosteronism and UNa are best done after withdrawal of antihypertensive medications, 36 this was not possible for safety reasons in high-risk patients with resistant hypertension. All patients were on a stable antihypertensive regimen for at least 4 weeks such that their sodium balance was likely in a steady state. Although different Aldosterone excess may play a pathophysiologic role in the relationship between hypertension and OSA. 28, 29 In a cross-sectional analysis of 114 patients with resistant hypertension, those at high risk for OSA (according to the Berlin Questionnaire) were almost twice as likely to have primary aldosteronism, tended to have lower PRA, and had signifi cantly greater 24-h Ualdo excretion compared with those at low risk for OSA. 30 However, the relationship between aldosterone levels and severity of OSA is unclear. In a prospective study, patients with moderate to severe OSA without coexisting cardiovascular disease and normal BP had a plasma aldosterone concentration and PRA similar to that of healthy subjects. 31 OSA is characterized by repetitive interruption of airfl ow during sleep caused by collapse of the pharyngeal airway. An anatomically small pharyngeal airway and enlarged peripharyngeal soft tissues resulting from obesity are common abnormalities in patients with OSA. Cross-sectional studies have used CT imaging and MRI to measure upper airway and soft tissue dimensions in the oropharyngeal region of patients with sleep-related breathing disorders. The volumes of the tongue and lateral walls of the upper airway independently increase the risk of OSA. 32 More recently, investigators demonstrated that severity of OSA is related to rostral fl uid displacement from the legs. 33 Furthermore, an observational study in patients with congestive heart failure demonstrated that sodium intake, according to food diary recordings, is directly, and renal function indirectly, related to the severity classes of antihypertensive medications have predictable effects on renin activity ( b -blockers suppressing and diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers increasing), medication effects on aldosterone excretion are less pronounced. 37, 38 It can be argued that assessment of salt intake on the basis of a single urine collection does not accurately refl ect dietary salt intake. However, patients were instructed to collect urine on a day when they were consuming their usual diet and going about their usual activities, prior to receiving dietary education.
In conclusion, the current study suggests that high dietary salt intake contributes to the severity of OSA in patients with resistant hypertension and hyperaldosteronism. Because the study is observational, causality cannot be determined. Interventional studies that use dietary salt restriction as a treatment strategy for OSA in patients with resistant hypertension and hyperaldosteronism are needed to test this hypothesis.
